These clinical results might be explained by the routine clinical administration of angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) drugs in patients with end-stage renal disease. This evidence concerns the gene ACE and stage 5 chronic kidney disease.